Which of the following is an FDA-approved indication for labetalol Hcl?

A. Acute myocardial infarction management often includes beta-blockers to reduce myocardial oxygen demand and prevent remodeling. However, labetalol is not the primary agent indicated specifically for the post-infarction period compared to metoprolol. It lacks the specific labeled indication for acute coronary syndromes. B. Hypertension is the primary FDA-approved indication for labetalol hydrochloride, including both chronic management and hypertensive emergencies. It functions as a non-selective beta-adrenergic and selective alpha-1 adrenergic receptor antagonist. This dual action reduces peripheral vascular resistance and maintains cardiac output. C. Heart failure with reduced ejection fraction typically requires specific beta-blockers like carvedilol or bisoprolol to improve survival. Labetalol is not officially indicated for the long-term management of chronic heart failure. Its potent alpha-blocking effects might lead to unfavorable hemodynamics in certain failure states. D. Ischemic stroke treatment focuses on reperfusion therapy and blood pressure stabilization within specific parameters. While labetalol is used to lower blood pressure in stroke patients, the stroke itself is not the indication. The drug is labeled for the hypertensive state, not the cerebrovascular event.